Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MDH1 | P40925 | 2/20 | 0.39 |
| ▸ | MDH2 | P40926 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660869 | 0.79 | NPC1 (0.43) | TRPV1RXFP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL29978611 | 0.77 | ALDH1A1 (0.52) | CYP3A4CYP19A1CYP2C9TRPV1MAPT | |
| SCHEMBL303909 | 0.77 | ALDH1A1 (0.52) | CYP3A4CYP19A1CYP2C9TRPV1MAPT | |
| SCHEMBL6757684 | 0.71 | KIF11 (0.50) | TRPV1PDE3BPDE3ANSD2 | |
| SCHEMBL2659983 | 0.70 | CASP3 (0.55) | MAPTPOLBALDH1A1 | |
| SCHEMBL6752 | 0.70 | ALDH1A1 (0.63) | MAPTRXFP1POLBALDH1A1 | |
| SCHEMBL29901720 | 0.70 | ALDH1A1 (0.63) | MAPTRXFP1POLBALDH1A1 | |
| SCHEMBL30871998 | 0.69 | DRD4 (0.59) | MAPTPDE3BPDE3APOLBALDH1A1 | |
| SCHEMBL1494348 | 0.69 | DRD4 (0.59) | MAPTPDE3BPDE3APOLBALDH1A1 | |
| SCHEMBL2001176 | 0.68 | MGLL (0.45) | MAPTRXFP1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125735-B1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2012-06-27 | — | — | EP | claimed |
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | US | claimed |
| US-8940900-B2 | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2125735-B1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2012-06-27 | — | — | EP | disclosed |
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, GCKR, GALK1 | CYP3A4 323/4885CYP19A1 1168/4885CYP2C9 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.